PharmaForceIQ has launched an AI visibility module to help pharmaceutical companies identify and correct inaccurate or outdated information in AI-generated answers.

PharmaForceIQ has launched a new tool to help pharmaceutical companies monitor how their medicines and disease education content appear in AI-generated answers.

Share of Answer (SOA), the latest module in the company’s Optichannel 360 platform, analyses responses generated by large language models (LLMs) to identify whether treatments are represented accurately, cited appropriately and positioned against competing therapies.

The launch comes as healthcare professionals (HCPs) and patients increasingly use AI tools to find information about diseases and treatment options, raising concerns about the accuracy and currency of the clinical information these systems provide.

According to PharmaForceIQ, its recent analyses found that official brand and disease websites accounted for just 17% of citations in AI-generated answers on average. The company also identified hundreds of references to retired webpages and instances of superseded FDA-approved labelling appearing in AI responses.

The findings highlight a potential problem for pharmaceutical companies seeking to ensure that AI platforms draw on current clinical evidence and approved product information.

Audits identify gaps in AI-generated medical information

PharmaForceIQ said its visibility audits have examined more than 10,000 AI-generated responses across branded and disease education programmes.

The company’s evaluation framework assesses four areas: whether a brand or treatment appears in relevant answers, whether the information is accurate, how the therapy is positioned against alternatives and whether the response cites authoritative sources.

The audits identified several examples of potentially misleading information.

In one analysis, AI-generated answers quoted superseded FDA-approved labelling in nearly 250 responses. The company also found that AI engines struggled to identify a rare disease when prompted using its abbreviation, despite correctly recognising the condition when given its full name. More than half of the answers failed to identify the disease when the abbreviation was used.

Such inconsistencies could affect how patients and clinicians interpret disease information and understand available treatment options.

Hemal Somaiya, chief executive and strategy officer at PharmaForceIQ, said: “We’ve seen a massive shift in how HCPs discover scientific information. When a clinician asks AI about a therapy, the answer should reflect accurate evidence that the brand stands behind instead of outdated information or unsupported claims.”

New module links monitoring with corrective action

Unlike tools that monitor how frequently brands are mentioned online, Share of Answer evaluates individual AI-generated responses and examines the claims within them.

The module identifies gaps in how therapies are represented and helps pharmaceutical companies establish an approved source of information governed by medical, legal and regulatory (MLR) review processes.

It then supports the publication of approved claims across relevant digital channels, with statements linked to their supporting sources so AI platforms can access and cite the information.

PharmaForceIQ said this approach is intended to move pharmaceutical companies beyond monitoring their visibility in AI-generated answers towards correcting inaccuracies and improving the availability of approved clinical information.

In a controlled test involving a subset of questions, the company reported that answer accuracy increased to between 94% and 100%. One AI engine improved from 40% to 95%.

However, PharmaForceIQ has not provided details of the test methodology, the AI engines assessed or the number of questions included in the controlled evaluation.

AI visibility becomes a commercial consideration

Share of Answer forms part of Optichannel 360, PharmaForceIQ’s commercial execution platform, which connects digital marketing with field-based pharmaceutical engagement.

The launch reflects a growing commercial interest in how pharmaceutical brands appear in AI-generated responses, particularly as traditional search engines and digital information channels evolve.

For pharmaceutical companies, the challenge is not simply ensuring that their products appear in AI answers, but that information about indications, clinical evidence and treatment options is accurate and supported by reliable sources.

PharmaForceIQ is positioning its new module as a way to address that challenge by combining AI visibility monitoring with content management and publication tools.

The company provides software and strategic services for pharmaceutical customer engagement across the product lifecycle.